Traders Purchase Large Volume of NewAmsterdam Pharma Put Options (NASDAQ:NAMS)

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) was the recipient of unusually large options trading on Thursday. Stock investors acquired 4,003 put options on the stock. This is an increase of 717% compared to the typical volume of 490 put options.

Insiders Place Their Bets

In related news, CAO Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $35.69, for a total value of $2,319,850.00. Following the transaction, the chief accounting officer directly owned 24,353 shares in the company, valued at $869,158.57. This trade represents a 72.75% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 12.74% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of institutional investors and hedge funds have recently modified their holdings of NAMS. Farther Finance Advisors LLC increased its stake in NewAmsterdam Pharma by 4,425.0% in the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after purchasing an additional 708 shares in the last quarter. Wells Fargo & Company MN grew its holdings in NewAmsterdam Pharma by 50.0% in the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after purchasing an additional 300 shares during the last quarter. KBC Group NV purchased a new position in shares of NewAmsterdam Pharma in the first quarter valued at $37,000. Navalign LLC purchased a new position in shares of NewAmsterdam Pharma in the fourth quarter valued at $46,000. Finally, Empowered Funds LLC acquired a new position in shares of NewAmsterdam Pharma during the 4th quarter worth $85,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Stock Down 0.6%

Shares of NASDAQ NAMS traded down $0.23 during midday trading on Thursday, hitting $35.60. The company had a trading volume of 164,361 shares, compared to its average volume of 1,029,626. The firm has a market capitalization of $4.16 billion, a price-to-earnings ratio of -19.87 and a beta of 0.08. NewAmsterdam Pharma has a twelve month low of $20.53 and a twelve month high of $42.21. The business has a 50-day simple moving average of $33.25 and a two-hundred day simple moving average of $33.12.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The company had revenue of $3.04 million for the quarter. On average, equities analysts forecast that NewAmsterdam Pharma will post -1.78 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently commented on NAMS. Truist Financial assumed coverage on shares of NewAmsterdam Pharma in a research note on Wednesday, March 18th. They issued a “buy” rating and a $57.00 target price for the company. Royal Bank Of Canada boosted their price target on shares of NewAmsterdam Pharma from $47.00 to $51.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 30th. Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $49.00.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.